A New Therapeutic Option for Migraine Sufferers: Axsome Therapeutics’ EMERGE Trial Results
On Monday, Axsome Therapeutics, Inc. (AXSM) made an exciting announcement regarding the EMERGE Phase 3 trial of their innovative migraine treatment, Symbravo, which combines MoSEIC meloxicam and rizatriptan. This combination therapy has shown promising results for patients who have not responded adequately to oral Calcitonin Gene-Related Peptide (CGRP) inhibitors, the most commonly used drugs for treating migraines.
What is Symbravo, and How Does it Work?
Symbravo is a novel co-formulation of two well-established drugs: meloxicam, a non-steroidal anti-inflammatory drug (NSAID), and rizatriptan, a serotonin receptor agonist. The combination of these two drugs aims to address both the inflammatory and vascular components of migraines. While CGRP inhibitors have been effective for many migraine sufferers, they don’t work for everyone. Approximately 30% of patients report inadequate response to these medications, highlighting the need for alternative therapeutic options.
EMERGE Trial Results
The EMERGE Phase 3 trial involved over 900 patients who had experienced at least two migraines per month despite trying oral CGRP inhibitors. The study’s primary endpoint was the number of patients achieving a 50% or greater reduction in migraine frequency (50% responder rate) during the 12-week treatment period. The trial results showed that Symbravo significantly outperformed placebo, with 43.7% of patients in the Symbravo group achieving the 50% responder rate, compared to 27.9% in the placebo group.
Implications for Migraine Sufferers
For individuals who have not responded to oral CGRP inhibitors, the EMERGE trial results provide hope for a more effective treatment option. Symbravo’s combination of meloxicam and rizatriptan addresses both the inflammatory and vascular aspects of migraines, potentially making it more effective for a broader range of patients. However, it is crucial to consult with a healthcare professional before making any changes to your current migraine treatment regimen.
Global Impact
The EMERGE trial results could have significant implications for the migraine community, as an estimated 12% of the global population experiences migraines. With approximately 30% of these individuals not responding to oral CGRP inhibitors, Symbravo could become an essential treatment option for those who have not found relief with other medications. Additionally, this success may encourage further research into combination therapies for various conditions, leading to the development of more effective treatments for a broader range of patients.
Conclusion
Axsome Therapeutics’ EMERGE Phase 3 trial results mark an important milestone in the treatment of migraines for those who have not responded adequately to oral CGRP inhibitors. Symbravo’s innovative combination of meloxicam and rizatriptan offers a potential solution by addressing both the inflammatory and vascular components of migraines. These findings could have significant implications for migraine sufferers worldwide, as well as the broader healthcare community, by encouraging further research into combination therapies for various conditions.
- Axsome Therapeutics’ EMERGE trial shows Symbravo (meloxicam and rizatriptan) significantly outperforms placebo for patients with inadequate response to oral CGRP inhibitors.
- Symbravo addresses both inflammatory and vascular components of migraines, potentially making it more effective for a broader range of patients.
- The EMERGE trial results could have significant implications for the migraine community and encourage further research into combination therapies for various conditions.
